이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

LIDDS 대차 대조표 상태

재무 상태 기준 확인 4/6

LIDDS 의 총 주주 지분은 SEK10.2M 이고 총 부채는 SEK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 SEK13.7M 및 SEK3.5M 입니다.

주요 정보

부채 비율

SEK 0

부채

이자 보상 비율	n/a
현금	SEK 10.95m
주식	SEK 10.19m
총 부채	SEK 3.48m
총 자산	SEK 13.67m

최근 재무 상태 업데이트

Recent updates

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

May 26

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Dec 15

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Jul 19

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Mar 08

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Nov 23

재무 상태 분석

단기부채: LIDDS 의 단기 자산 ( SEK12.2M )이 단기 부채( SEK2.6M ).

장기 부채: LIDDS 의 단기 자산( SEK12.2M )이 장기 부채( SEK900.0K ).

부채 대 자본 내역 및 분석

부채 수준: LIDDS 부채가 없습니다.

부채 감소: LIDDS 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: LIDDS 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 4.6 %의 역사적 비율로 계속 감소할 경우 LIDDS 의 현금 활주로는 1년 미만입니다.

LIDDS 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Recent updates

LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

New major risk - Shareholder dilution

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기